Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesBecton Dickinson & Co.

Becton Dickinson & Co.

PortfolioPortfolio WatchlistWatchlist
Company price
194.16 GBX -0.83 ( 0.43%)
Last update at 2026-10-27T16:53:00Z
VOLUME
370
Market Cap
4265717.35M
P/E
0.25

Momentum Score

…

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
194.16
Low
197.51
High
52 Week Price Range
125.47
Low
198.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Becton Dickinson & Co. manufactures medical devices, instrument systems and consumables used across hospitals, laboratories and ambulatory care. Long-term growth may be supported by demographic-driven healthcare demand, expanding diagnostics and recurring consumable sales alongside geographic expansion. The company appears positioned with diversified product lines and leading market shares in several categories that could support steady demand.

Main risks include regulatory and reimbursement pressure, product-liability and litigation exposure, and execution risk from acquisitions and capital-equipment cyclicality.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
194.99
Dividend Yield
2.67%
Revenue TTM
21924.00M
Revenue Per Share
76.48
Gross Profit TTM
10257.00M
Debt / Equity
0.82
ROE
6.96%
Net Debt
19873.00M
ROCE
5.31%
Diluted EPS TTM
6.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax 1882.00M 2005.00M 1662.00M 1783.00M 1692.00M
Net income 1678.00M 1705.00M 1470.00M 1545.00M 1514.00M
Selling general administrative - - - - 4868.00M
Gross profit 9924.00M 9125.00M 8823.00M 8614.00M 8820.00M
Ebit 2495.00M 2533.00M 2751.00M 2636.00M 2821.00M
Ebitda 4957.00M 4677.00M 5039.00M 4865.00M 5051.00M
Depreciation and amortization 2462.00M 2144.00M 2288.00M 2229.00M 2230.00M
Operating income 2578.00M 3087.00M 2751.00M 2636.00M 2821.00M
Other operating expenses 19262.00M 17091.00M 17307.00M 16705.00M 16979.00M
Interest expense 613.00M 528.00M - - 0.00M
Tax provision - - - - 150.00M
Interest income - - - - 373.00M
Income tax expense 204.00M 300.00M 132.00M 148.00M 88.00M
Total revenue 21839.00M 20178.00M 19372.00M 18870.00M 19131.00M
Total operating expenses 7347.00M 6038.00M 6758.00M 6449.00M 6668.00M
Cost of revenue 11915.00M 11053.00M 10549.00M 10256.00M 10311.00M
Total other income expense net -696.00M -1082.00M -1089.00M -853.00M -1129.00M
Discontinued operations - - - 144.00M 488.00M
Net income applicable to common shares - - - 1689.00M 2002.00M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 55325.00M 57286.00M 52780.00M 52934.00M 53866.00M
Intangible assets 2994.00M 10917.00M 10948.00M 12310.00M 12773.00M
Other current assets 1508.00M 1291.00M 1445.00M 1712.00M 1450.00M
Total liab 29936.00M 31396.00M 26984.00M 27652.00M 30189.00M
Total stockholder equity 25390.00M 25890.00M 25796.00M 25282.00M 23677.00M
Other current liab 4644.00M 4606.00M 5000.00M 6112.00M 4887.00M
Common stock 371.00M 371.00M 371.00M 365.00M 365.00M
Retained earnings 16622.00M 16139.00M 15535.00M 15157.00M 13826.00M
Other liab - - - 5571.00M 6109.00M
Good will 33023.00M 26465.00M 24522.00M 24621.00M 23886.00M
Other assets - - 1560.00M 1368.00M 1920.00M
Cash 851.00M 1856.00M 1416.00M 1006.00M 2283.00M
Total current liabilities 8313.00M 8956.00M 6641.00M 7811.00M 6626.00M
Net debt 19873.00M 19205.00M -1416.00M -1006.00M -2283.00M
Short term debt 1695.00M 2454.00M - - 500.00M
Short long term debt total 20724.00M 21061.00M - - 17110.00M
Other stockholder equity 10267.00M 11087.00M 9890.00M 9758.00M 9484.00M
Property plant equipment - - - 6494.00M 6449.00M
Total current assets 9255.00M 10468.00M 8676.00M 8141.00M 8838.00M
Net tangible assets - - - -11651.00M -12984.00M
Short term investments 8.00M 445.00M 8.00M 8.00M 12.00M
Net receivables 2994.00M 3033.00M 2534.00M 2191.00M 2350.00M
Long term debt - - - - 17110.00M
Inventory 3894.00M 3843.00M 3273.00M 3224.00M 2743.00M
Accounts payable 1974.00M 1896.00M 1641.00M 1699.00M 1739.00M
Accumulated other comprehensive income -1870.00M -1707.00M - - -
Treasury stock - - - - -7723.00M
Non currrent assets other 3056.00M 1739.00M -42544.00M -43425.00M -43108.00M
Non current assets total 46070.00M 46818.00M 42544.00M 43425.00M 43108.00M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Change to liabilities - - - -473.00M 660.00M
Total cashflows from investing activities -818.00M -5514.00M - -3220.00M -1843.00M
Net borrowings - - - -78.00M -243.00M
Total cash from financing activities -3617.00M 2087.00M -1956.00M -591.00M -3306.00M
Change to operating activities - - - -436.00M -184.00M
Net income 1678.00M 1705.00M 1484.00M 1779.00M 2092.00M
Change in cash -1005.00M 375.00M 322.00M -1233.00M -525.00M
Begin period cash flow 1856.00M 1481.00M 1159.00M 2392.00M 2917.00M
End period cash flow 851.00M 1856.00M 1481.00M 1159.00M 2392.00M
Total cash from operating activities 3430.00M 3798.00M 2989.00M 2634.00M 4647.00M
Depreciation 2462.00M 2144.00M 2288.00M 2229.00M 2230.00M
Other cashflows from investing activities -480.00M -444.00M - -177.00M -141.00M
Dividends paid 1196.00M 1100.00M 1114.00M 1082.00M 1048.00M
Change to inventory -410.00M 98.00M -15.00M -631.00M -83.00M
Change to account receivables 71.00M -453.00M -290.00M 32.00M -61.00M
Sale purchase of stock -1000.00M -500.00M - -500.00M -1750.00M
Other cashflows from financing activities -87.00M -88.00M 1313.00M 1796.00M 4604.00M
Change to netincome - - - 269.00M -44.00M
Capital expenditures 760.00M 725.00M 874.00M 973.00M 1194.00M
Change in working capital -493.00M -184.00M -305.00M -599.00M -144.00M
Stock based compensation - - 261.00M 240.00M 238.00M
Other non cash items -217.00M 344.00M -739.00M -1015.00M 231.00M
Free cash flow 2670.00M 3073.00M 2115.00M 1661.00M 3453.00M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0R19
Becton Dickinson & Co.		 -0.83
0.43%		 194.16 0.25 - 1.95 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Becton Dickinson & Co.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880

201 847 6800

https://www.bd.com

70000

Name Title Year Born
Mr. Thomas E. Polen Jr. Pres, CEO & Chairman 1973
Mr. Christopher DelOrefice Exec. VP & CFO 1971
Mr. Samrat S. Khichi Esq. Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel 1967
Mr. Thomas J. Spoerel Sr. VP, Controller & Chief Accounting Officer 1978
Ms. Elizabeth McCombs Exec. VP & Chief Technology Officer 1976
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board NA
Ms. Denise Fleming Exec. VP of Technology & Global Services and Chief Information Officer NA
Ms. Francesca M. DeMartino Sr. VP & Head of Investor Relations NA
Michelle Quinn Sr. VP and Chief Ethics & Compliance Officer NA
Troy Kirkpatrick VP of PR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…